	US 12,357,601 B2
	Composition for inhibiting growth of bacterium having menaquinone synthesis pathway through futalosine or futalosine derivative
Hidenori Matsui, Tokyo (JP); and Marina Kawaguchi, Kyoto (JP)
Assigned to NOSTER INC., Kyoto (JP)
Filed by NOSTER INC., Kyoto (JP)
Filed on Apr. 28, 2022, as Appl. No. 17/732,057.
Application 17/732,057 is a division of application No. 16/494,661, granted, now 11,337,947, previously published as PCT/JP2018/006804, filed on Feb. 23, 2018.
Claims priority of application No. 053056/2017 (JP), filed on Mar. 17, 2017.
Prior Publication US 2023/0285343 A1, Sep. 14, 2023
Int. Cl. A61K 31/201 (2006.01); C07K 14/205 (2006.01); A61K 38/00 (2006.01)

CPC A61K 31/201 (2013.01) [C07K 14/205 (2013.01); A61K 38/00 (2013.01)]

9 Claims

1. A method for preventing development of a disease selected from the group consisting of acute gastritis, chronic gastritis, nodular gastritis, stomach cancer, stomach MALT lymphoma, diffuse large B-cell lymphoma, idiopathic thrombocytopenia purpura, chronic urticaria, and Parkinson's disease in a patient infected with Helicobacter pylori or Helicobacter suis comprising administering a fatty acid having 18 carbon atoms and a hydroxyl group at the 10-position to a subject.